Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with
advanced-stage hepatocellular carcinoma (HCC). Two different ICI-containing regimens …

Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …

Simple Summary The search for non-invasive biomarkers is a hot topic in modern oncology,
since a tissue biopsy has significant limitations in terms of cost and invasiveness. The …

A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown
superiority compared to sorafenib and is now being used as the systemic treatment of choice …

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment
for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the …

Hepatocellular carcinoma (HCC) presents significant treatment challenges despite
considerable advancements in its management. The Indian National Association for the …

Background Lenvatinib and atezolizumab plus bevacizumab (A+ B) have been used for
unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies …

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative
approach in treating advanced hepatocellular carcinoma (HCC). Despite their success …

The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a
serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of …